A recent network meta-analysis involving 1476 participants concluded that combining standard therapy with GLP-1 RAs offers superior metabolic and hormonal outcomes in PCOS compared to standard therapy alone [49]. The gene discussed is GLP1R; the disease is polycystic ovary syndrome.